Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra : a case report

• Published in: Clinical and experimental rheumatology 2007-09, Vol.25 (5), p.758-759
• Main Authors: GUIGNARD, S, DIEN, G, DOUGADOS, M
• Format: Article
• Language: English
• Subjects: Adult; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Biological and medical sciences; Diseases of the osteoarticular system; Humans; Immunomodulators; Inflammatory joint diseases; Interleukin 1 Receptor Antagonist Protein - adverse effects; Interleukin 1 Receptor Antagonist Protein - therapeutic use; Interleukin-1 - antagonists & inhibitors; Interleukin-1 - physiology; Male; Medical sciences; Pharmacology. Drug treatments; Pneumology; Respiratory Distress Syndrome, Adult - chemically induced; Respiratory system : syndromes and miscellaneous diseases; Still's Disease, Adult-Onset - drug therapy; Still's Disease, Adult-Onset - physiopathology; Systemic Inflammatory Response Syndrome - chemically induced; Systemic Inflammatory Response Syndrome - diagnosis
• ISSN: 0392-856X; 1593-098X

Interleukin 1 (IL1) plays an important role in adult onset Still's disease. Anakinra (Kineret), a recombinant IL1 Receptor Antagonist (IL 1 RA) was therefore recently proposed in adult onset Still's disease with great efficacy. Anakinra appeared to be well tolerated and safe. The case of a patient with refractory adult onset Still's disease who experienced a Systemic Inflammatory Response Syndrome and Adult Respiratory Distress Syndrome requiring intensive care unit hospitalization 10 days after the introduction of anakinra is reported.